Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker
NCT ID: NCT00185120
Last Updated: 2012-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
152 participants
INTERVENTIONAL
2005-09-30
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Olmesartan in Essential Hypertension
NCT00185172
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.
NCT01033071
Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
NCT00430950
Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
NCT00890591
Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
NCT00846365
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Olmesartan medoxomil
Hydroclorothiazide
Benazepril
Amlodipine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with high blood pressure
Exclusion Criteria
* History of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina pectoris within the past 6 months
* Type 1 diabetes mellitus
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daiichi Sankyo
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mobile, Alabama, United States
Memorial Research Medical Center
Long Beach, California, United States
National Research Institute
Los Angeles, California, United States
Clinical Trials Research
Roseville, California, United States
Apex Research Institute
Santa Ana, California, United States
Orange County Research Center
Tustin, California, United States
Westlake Medical Center
Westlake Village, California, United States
Clinical Research of South Florida
Coral Gables, Florida, United States
The Greater Fort Lauderdale Heart Group Research
Fort Lauderdale, Florida, United States
SFBC International
Miami, Florida, United States
CLIRECO, Inc.
Tamarac, Florida, United States
Midwest Institute for Clinical Research
Indianapolis, Indiana, United States
Heartland Research Associates
Wichita, Kansas, United States
Androscoggin Cardiology Research
Auburn, Maine, United States
Internal Medicine Associates of Charlotte
Charlotte, North Carolina, United States
Piedmont Medical Research Associates
Winston-Salem, North Carolina, United States
The Lindner Clinical Trial Center
Cincinnati, Ohio, United States
Omega Medical Research
Warwick, Rhode Island, United States
Volunteer Research Group, University of Tennessee Med. Ctr.
Knoxville, Tennessee, United States
Punzi Medical Center
Carrollton, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
866-447
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.